Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
13.30
-0.06 (-0.45%)
Jun 12, 2026, 4:00 PM EDT - Market closed
Dr. Reddy's Laboratories Employees
Dr. Reddy's Laboratories had 27,527 employees as of March 31, 2026. The number of employees decreased by 284 or -1.02% compared to the previous year.
Employees
27,527
Change (1Y)
-284
Growth (1Y)
-1.02%
Revenue / Employee
$130,151
Profits / Employee
$16,601
Market Cap
11.16B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 27,527 | -284 | -1.02% |
| Mar 31, 2025 | 27,811 | 763 | 2.82% |
| Mar 31, 2024 | 27,048 | 1,185 | 4.58% |
| Mar 31, 2023 | 25,863 | 1,068 | 4.31% |
| Mar 31, 2022 | 24,795 | 2,056 | 9.04% |
| Mar 31, 2021 | 22,739 | 1,089 | 5.03% |
| Mar 31, 2020 | 21,650 | -316 | -1.44% |
| Mar 31, 2019 | 21,966 | -1,558 | -6.62% |
| Mar 31, 2018 | 23,524 | 853 | 3.76% |
| Mar 31, 2017 | 22,671 | 496 | 2.24% |
| Mar 31, 2016 | 22,175 | 1,802 | 8.85% |
| Mar 31, 2015 | 20,373 | 1,952 | 10.60% |
| Mar 31, 2014 | 18,421 | 1,804 | 10.86% |
| Mar 31, 2013 | 16,617 | 1,417 | 9.32% |
| Mar 31, 2012 | 15,200 | 277 | 1.86% |
| Mar 31, 2011 | 14,923 | 1,468 | 10.91% |
| Mar 31, 2010 | 13,455 | 2,227 | 19.83% |
| Mar 31, 2009 | 11,228 | 1,653 | 17.26% |
| Mar 31, 2008 | 9,575 | 555 | 6.15% |
| Mar 31, 2007 | 9,020 | 1,495 | 19.87% |
| Mar 31, 2006 | 7,525 | 1,390 | 22.66% |
| Mar 31, 2005 | 6,135 | -20 | -0.32% |
| Mar 31, 2004 | 6,155 | 303 | 5.18% |
| Mar 31, 2003 | 5,852 | 409 | 7.51% |
| Mar 31, 2002 | 5,443 | 314 | 6.12% |
| Mar 31, 2001 | 5,129 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Viatris | 30,000 |
| Elanco Animal Health | 9,900 |
| Amneal Pharmaceuticals | 8,700 |
| Hims & Hers Health | 2,442 |
| Alkermes | 2,050 |
| Neurocrine Biosciences | 2,000 |
| United Therapeutics | 1,400 |
| Lantheus Holdings | 1,193 |
RDY News
- 5 hours ago - Dr. Reddy’s announces first-to-market launch of Bosutinib Tablets 400mg - TheFly
- 1 day ago - Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States - Business Wire
- 1 day ago - Dr. Reddy's launches Bosutinib Tablets 400mg in the United States - Business Upturn
- 3 days ago - Nomura on Pharma May 2026: Torrent leads semaglutide with 19% market share, Sun gains; Alkem and Dr Reddy's lag market - Business Upturn
- 9 days ago - Dr. Reddy's Laboratories issues 12,100 equity shares under stock options scheme - Business Upturn
- 15 days ago - Dr. Reddy's files 20-F annual report with US SEC for fiscal year ended March 31, 2026 - Business Upturn
- 16 days ago - NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY - PRNewsWire
- 17 days ago - Dr Reddy’s to ring closing bell at NYSE to mark 25 years of its listing - The Times of India